Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed, a US-China Company, Closes $85 Million Series B Round

publication date: Aug 27, 2018

Harbour BioMed completed an $85 million Series B financing, which it will use to advance its pipeline that includes both clinical and discovery stage programs. GIC, Singapore's sovereign wealth fund, led the financing. Formed in late 2016, Harbour started with an initial $50 million in capital and immediately acquired Harbour Antibodies BV, a Dutch company with two proprietary transgenic mouse platforms, though Harbour has been actively in-licensing drug development projects. The company is headquartered in Boston, with R&D operations in Shanghai and the antibody platform in Rotterdam. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital